Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability

Clinica Chimica Acta

Volumn 449, Issue , 2015, Pages 9-15

  Fourier, Anthony ^a,b   Portelius, Erik ^d   Zetterberg, Henrik ^d,e   Blennow, Kaj ^d   Quadrio, Isabelle ^a,b   Perret Liaudet, Armand ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Société Française de Biologie Clinique SFBC Alzheimer Biomarkers group co coordination   (France)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer diagnosis; Analytical confounders; Biomarkers; CSF; Dementia; Pre analytical confounders

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ACCURACY; ADSORPTION; ALZHEIMER DISEASE; BINDING AFFINITY; CENTRIFUGATION; CEREBROSPINAL FLUID; DISEASE MARKER; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; FREEZE THAWING; FREEZING; LUMBAR PUNCTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REPRODUCIBILITY; REVIEW; ROOM TEMPERATURE; DEVICES; HUMAN; LABORATORY TEST; NEUROLOGIC EXAMINATION; STANDARDS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 84940435280     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.05.024     Document Type: Review

References (53)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Salloway S., Sperling R., Fox N.C., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370:322-333.
3. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
4. Dubois B., Feldman H.H., Jacova C., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014, 13:614-629.
5. McKhann G.M., Knopman D.S., Chertkow H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
6. Teunissen C.E., de Vente J., Steinbusch H.W., De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging 2002, 23:485-508.
7. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
8. Lewczuk P., Lelental N., Spitzer P., Maler J.M., Kornhuber J. Amyloid-beta 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. J. Alzheimers Dis. 2015, 43:183-191.
9. Slaets S., Le Bastard N., Martin J.J., et al. Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J. Alzheimers Dis. 2013, 36:759-767.
10. Sauvee M., Didierlaurent G., Latarche C., Escanye M.C., Olivier J.L., Malaplate-Armand C. Additional use of Abeta42/Abeta40 ratio with cerebrospinal fluid biomarkers P-Tau and Abeta42 increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice. J. Alzheimers Dis. 2014, 41:377-386.
11. Molinuevo J.L., Blennow K., Dubois B., et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2014, 10:808-817.
12. Verwey N.A., van der Flier W.M., Blennow K., et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 2009, 46:235-240.
13. Hort J., Bartos A., Pirttila T., Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur. J. Neurol. 2010, 17:90-96.
14. Vanderstichele H., Bibl M., Engelborghs S., et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2012, 8:65-73.
15. Mattsson N., Andreasson U., Persson S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011, 7:386-395.
16. Bjerke M., Portelius E., Minthon L., et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int. J. Alzheimers Dis. 2010, 2010. 10.4061/2010/986310.
17. Perret-Liaudet A., Pelpel M., Tholance Y., et al. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J. Alzheimers Dis. 2012, 31:13-20.
18. Schoonenboom N.S., Mulder C., Vanderstichele H., et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem. 2005, 51:189-195.
19. Chevallier S., Monti M., Michel P., Vollenweider P. Lumbar puncture. Rev. Med. Suisse 2008, 4:2312-2314.
20. Dieterich M. Post-lumbar puncture headache syndrome. Neurologic disorders: course and treatment 1996, 59. E.A. Press (Ed.).
21. Lavi R., Yarnitsky D., Rowe J.M., Weissman A., Segal D., Avivi I. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology 2006, 67:1492-1494.
22. del Campo M., Mollenhauer B., Bertolotto A., et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark. Med 2012, 6:419-430.
23. Kim M., Yoon H. Comparison of post-dural puncture headache and low back pain between 23 and 25 gauge Quincke spinal needles in patients over 60years: randomized, double-blind controlled trial. Int. J. Nurs. Stud. 2011, 48:1315-1322.
24. Lewczuk P., Beck G., Esselmann H., et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin. Chem. 2006, 52:332-334.
25. Pica-Mendez A.M., Tanen M., Dallob A., Tanaka W., Laterza O.F. Nonspecific binding of Abeta42 to polypropylene tubes and the effect of Tween-20. Clin. Chim. Acta 2010, 411:1833.
26. Poncin-Epaillard F., Mille C., Debarnot D., et al. Study of the adhesion of neurodegenerative proteins on plasma-modified and coated polypropylene surfaces. J. Biomater. Sci. Polym. Ed. 2011, 23:1879-1893.
27. Toombs J., Paterson R.W., Schott J.M., Zetterberg H. Amyloid-beta 42 adsorption following serial tube transfer. Alzheimers Res. Ther. 2014, 6:5.
28. Toombs J., Paterson R.W., Lunn M.P., et al. Identification of an important potential confound in CSF AD studies: aliquot volume. Clinical chemistry and laboratory medicine: CCLM/FESCC 2013, 51:2311-2317.
29. Lehmann S., Schraen S., Quadrio I., et al. Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. Alzheimers Dement. 2014, 10:S390-S394.
30. Kaiser E., Schonknecht P., Thomann P.A., Hunt A., Schroder J. Influence of delayed CSF storage on concentrations of phospho-tau protein (181), total tau protein and beta-amyloid (1-42). Neurosci. Lett. 2007, 417:193-195.
31. Rosenling T., Slim C.L., Christin C., et al. The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J. Proteome Res. 2009, 8:5511-5522.
32. You J.S., Gelfanova V., Knierman M.D., Witzmann F.A., Wang M., Hale J.E. The impact of blood contamination on the proteome of cerebrospinal fluid. Proteomics 2005, 5:290-296.
33. Zimmermann R., Lelental N., Ganslandt O., Maler J.M., Kornhuber J., Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimers Dis. 2011, 25:739-745.
34. Le Bastard N., De Deyn P.P., Engelborghs S. Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin. Chem. 2015, 61:734-743.
35. Simonsen A.H., Bahl J.M., Danborg P.B., et al. Pre-analytical factors influencing the stability of cerebrospinal fluid proteins. J. Neurosci. Methods 2013, 215:234-240.
36. Sjogren M., Vanderstichele H., Agren H., et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93years of age: establishment of reference values. Clin. Chem. 2001, 47:1776-1781.
37. Bibl M., Esselmann H., Otto M., et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25:2912-2918.
38. Mattsson N., Andreasson U., Persson S., et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013, 9:251-261.
39. Schipke C.G., Jessen F., Teipel S., et al. Long-term stability of Alzheimer's disease biomarker proteins in cerebrospinal fluid. J. Alzheimers Dis. 2011, 26:255-262.
40. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666-669.
41. Moghekar A., Goh J., Li M., Albert M., O'Brien R.J. Cerebrospinal fluid Abeta and tau level fluctuation in an older clinical cohort. Arch. Neurol. 2012, 69:246-250.
42. Slats D., Claassen J.A., Spies P.E., et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol. Aging 2011, 33(831):e831-e839.
43. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 2001, 310:173-186.
44. Lewczuk P., Beck G., Ganslandt O., et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 2006, 409:1-4.
45. Olsson A., Vanderstichele H., Andreasen N., et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2005, 51:336-345.
46. Mattsson N., Zetterberg H., Hansson O., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
47. Jongbloed W., Kester M.I., van der Flier W.M., et al. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimers Dement. 2013, 9:276-283.
48. Schipke C.G., Prokop S., Heppner F.L., Heuser I., Peters O. Comparison of immunosorbent assays for the quantification of biomarkers for Alzheimer's disease in human cerebrospinal fluid. Dement. Geriatr. Cogn. Disord. 2011, 31:139-145.
49. Carrillo M.C., Blennow K., Soares H., et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 2013, 9:137-140.
50. Korecka M., Waligorska T., Figurski M., et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta(4)(2) in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J. Alzheimers Dis. 2014, 41:441-451.
51. Leinenbach A., Pannee J., Dulffer T., et al. Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-beta in cerebrospinal fluid. Clin. Chem. 2014, 60:987-994.
52. McAvoy T., Lassman M.E., Spellman D.S., et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 2014, 60:683-689.
53. Teunissen C.E., Verwey N.A., Kester M.I., van Uffelen K., Blankenstein M.A. Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), Tau, and phosphorylated Tau in Alzheimer's disease: report of an international workshop. Int. J. Alzheimers Dis. 2010, 2010.